2136 Does concurrent chemotherapy improve local control and survival over radiotherapy alone or induction chemotherapy in stage III non-small cell lung cancer (NSCLC)? Results at 3 years in 140 patients (PTS) with a minimum follow-up of 24 months

1996 ◽  
Vol 36 (1) ◽  
pp. 344
Author(s):  
F. Reboul ◽  
Y. Brewer ◽  
P. Vincent ◽  
B. Chauvet ◽  
C.Félix Faure ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Chemotherapy ◽  
Local Control ◽  
Cell Lung Cancer ◽  
Concurrent Chemotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Radiotherapy Alone

Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non–Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group

2006 ◽  
Vol 24 (27) ◽  
pp. 4397-4404 ◽  
Author(s):  
Rudolf M. Huber ◽  
Michael Flentje ◽  
Michael Schmidt ◽  
Barbara Pöllinger ◽  
Helga Gosse ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Chemotherapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Time To Progression ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Radiotherapy Alone

Purpose The aim of this study was to examine whether, after preceding induction chemotherapy, simultaneous chemoradiotherapy is superior to radiotherapy alone. Patients and Methods Patients with non–small-cell lung cancer in inoperable stage IIIA or IIIB received induction chemotherapy with two cycles of paclitaxel 200 mg/m2 and carboplatin area under the curve 6 every 3 weeks. Patients without progression at restaging after induction chemotherapy were randomly assigned to radiotherapy (60 Gy) or chemoradiotherapy (paclitaxel 60 mg/m2 weekly). The primary end point was overall survival; secondary end points were time to progression, response, and toxicity. Results Three hundred three patients entered the study, and 276 completed induction chemotherapy. Two hundred fourteen patients were randomly assigned (radiotherapy alone: n = 113; simultaneous chemoradiotherapy: n = 101). Median follow-up time of all randomly assigned patients was 13.6 months (interquartile range [IQR], 6.4 to 29.0 months), and median follow-up time of the subgroup of censored patients (n = 52) was 37.4 months (IQR, 5.9 to 57.0 months; maximum, 76.1 months). Toxicities during the induction phase were mild. During radiotherapy, overall toxicity rates were not significantly different between the two arms. Median survival times in the radiotherapy group and chemoradiotherapy group were 14.1 months (95% CI, 11.8 to 16.3 months) and 18.7 months (95% CI, 14.1 to 23.3 months; difference not statistically significant, P = .091). Median time to progression significantly favored simultaneous chemoradiotherapy (11.5 months; 95% CI, 8.3 to 14.7 months) versus radiotherapy alone (6.3 months; 95% CI, 5.0 to 7.6 months; P < .001, log-rank test). Conclusion Induction chemotherapy followed by chemoradiotherapy with weekly paclitaxel is feasible. Response, time to progression, and survival favor chemoradiotherapy compared with radiotherapy alone.

Dose-painting radiation with concurrent chemotherapy for locally advanced non-small cell lung cancer: A single-center observational study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20529-e20529
Author(s):  
Jiahua Lv ◽  
Junchao Wang ◽  
Hongyuan Jia ◽  
Long Liang ◽  
Lei Wu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Concurrent Chemotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Dose Painting ◽  
Integrated Boost

e20529 Background: Dose-painting radiotherapy is a promising technique which enables different dose distribution to different areas within the lung cancer. However, the efficacy and safety of this irradiation technique are still uncertain. In this study, we observed and analyzed the outcomes of dose-painting radiotherapy with chemotherapy for the locally advanced non-small cell lung cancer. Methods: Patients with stage III non-small cell lung cancer undergoing chemoradiotherapy were enrolled in this study. The dose-painting target was defined according to the distance between the tumor and the mediastinum (GTVwithin 2cm and GTVout-of 2cm). Doses of 60-80 Gy( 3-4Gy/fraction, bid) and 40-60 Gy (2-3Gy/fraction, bid) were prescribed to the GTVwithin 2cm and GTVout-of 2cm, respectively, in 20 fractions, using simultaneous integrated boost. All the patients received 2-4 cycles of chemotherapy using cisplatin plus paclitaxel or pemetrexed. Results: In total, 65 patients were included in this study. Median follow-up was 66.1 months (range 8.0-117.3months). The incidence of ≥Grade 2 radiation pneumonitis and esophagitis were was 30.8% and 38.5%, respectively. The 1, 3, 5-year OS and PFS were 78.4% and 58.5%, 32.3% and 26.1%, 18.5% and 13.8%, respectively. Late radiation esophagitis were seen in 3 patients and 2 patients were observed severe pulmonary fibrosis. None of the patients experienced fatal bronchopulmonary hemorrhage or tracheal fistula. Conclusions: Radiation dose painting with concurrent chemotherapy is feasible and well tolerated for locally advanced non-small cell lung cancer. It needs to be further confirmed by large randomized controlled clinical studies.

Sign in / Sign up

Export Citation Format

Share Document